MX2013011591A - Métodos y composiciones para tratar enfermedades neurodegenerativas. - Google Patents

Métodos y composiciones para tratar enfermedades neurodegenerativas.

Info

Publication number
MX2013011591A
MX2013011591A MX2013011591A MX2013011591A MX2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A MX 2013011591 A MX2013011591 A MX 2013011591A
Authority
MX
Mexico
Prior art keywords
compositions
methods
neurodegenerative diseases
treating neurodegenerative
treating
Prior art date
Application number
MX2013011591A
Other languages
English (en)
Inventor
William C Shakespeare
Frank G Haluska
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2013011591A publication Critical patent/MX2013011591A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención describe métodos y composiciones para tratar o prevenir una enfermedad neurodegenerativa, mediante la administración de un compuesto de la Fórmula I: o una sal, solvato o hidrato farmacéuticamente aceptable del mismo, en donde las variables son tal como se define en la presente invención.
MX2013011591A 2011-04-07 2012-04-06 Métodos y composiciones para tratar enfermedades neurodegenerativas. MX2013011591A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472961P 2011-04-07 2011-04-07
US201161518427P 2011-05-05 2011-05-05
PCT/US2012/032566 WO2012139027A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
MX2013011591A true MX2013011591A (es) 2014-04-14

Family

ID=46969573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011591A MX2013011591A (es) 2011-04-07 2012-04-06 Métodos y composiciones para tratar enfermedades neurodegenerativas.

Country Status (11)

Country Link
US (1) US20140045826A1 (es)
EP (1) EP2694064A1 (es)
JP (1) JP2014510154A (es)
KR (1) KR20140022063A (es)
CN (1) CN103582478A (es)
AU (1) AU2012240026A1 (es)
BR (1) BR112013024171A2 (es)
CA (1) CA2832483A1 (es)
EA (1) EA201391485A1 (es)
MX (1) MX2013011591A (es)
WO (1) WO2012139027A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN103421005A (zh) * 2012-05-16 2013-12-04 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) * 2012-12-13 2016-05-05 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
WO2015085971A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
CN104496940B (zh) * 2014-01-06 2017-03-15 广东东阳光药业有限公司 一种制备bcr‑abl抑制剂中间体的方法
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
JP6570776B2 (ja) * 2016-06-20 2019-09-04 テグ−キョンプク メディカル イノベーション ファウンデーション 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
US11117883B2 (en) * 2016-12-15 2021-09-14 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-Kit inhibitors
CN108399315B (zh) * 2018-03-01 2022-02-22 中国科学院长春应用化学研究所 一种Bcr-Abl蛋白激酶抑制剂的筛选方法
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
CN113825543A (zh) 2019-03-19 2021-12-21 勃林格殷格翰动物保健美国公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
WO2020223235A1 (en) * 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
EA202193211A1 (ru) 2019-06-11 2022-03-30 Сан Фарма Эдванст Рисерч Компани Лтд. Лечение синуклеопатий
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
GB202019874D0 (en) * 2020-12-16 2021-01-27 Benevolentai Bio Ltd New compounds and methods
WO2022225972A1 (en) * 2021-04-19 2022-10-27 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087901A2 (en) * 2003-03-25 2004-10-14 Wyeth Brain-localized protein kinases homologous to homeodomain-interacting protein kinases
ES2761180T3 (es) * 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo

Also Published As

Publication number Publication date
EA201391485A1 (ru) 2014-03-31
CN103582478A (zh) 2014-02-12
JP2014510154A (ja) 2014-04-24
CA2832483A1 (en) 2012-10-11
WO2012139027A1 (en) 2012-10-11
BR112013024171A2 (pt) 2016-12-13
KR20140022063A (ko) 2014-02-21
US20140045826A1 (en) 2014-02-13
EP2694064A1 (en) 2014-02-12
AU2012240026A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
PH12019500480A1 (en) Pyridine compound
PH12017501429A1 (en) Derivatives of betulin
MX2011009796A (es) Inhibidores de la cinasa pi3.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MY176488A (en) 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
NZ712207A (en) Tetrahydropyrrolothiazine compounds
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX349159B (es) Derivados deuterados de ivacaftor.
MY176126A (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
IN2014KN00948A (es)
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
WO2013074905A3 (en) Compounds, compositions, pharmaceutical compositions, and methods of use
TN2011000507A1 (en) Inhibitors of pi3 kinase and / or mtor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal